Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.

home / articles / ALEC - Alector Upgraded Analyst Sees High Reward Potential Ahead of Alzheimer's Disease Candidate's Phase 2 Results | Benzinga

ALEC - Alector Upgraded Analyst Sees High Reward Potential Ahead of Alzheimer's Disease Candidate's Phase 2 Results | Benzinga

Alector Inc.

Stifel has upgraded Alector Inc (NASDAQ: ALEC), noting that while Alzheimer's is a very high risk, the probability of success for AL002 (TREM2 agonist) is above average, and the stock risk/reward is highly attractive ahead of phase 2 data in expected in Q4 2024.

In September, Alector completed enrollment in the INVOKE-2 Phase 2 trial of AL002 for slowing disease progression in individuals with early Alzheimer's disease.

The analyst downgraded ALEC in 2022 after becoming more skeptical about the prospects of AL001 in frontotemporal dementia due to a Full story available on Benzinga.com
Stock Information
Company Name: Alector Inc.
Stock Symbol: ALEC
Market: NYSE
Website: alector.com
Menu
ALEC ALEC Quote ALEC Short ALEC News ALEC Articles ALEC Message Board
Get ALEC Alerts

News, Short Squeeze, Breakout and More Instantly...